CGRP Forum is made possible thanks to support from AbbVie, Lilly, Organon and Pfizer, all of whom have no influence or control of editorial content. More information is available here »
Philadelphia, USA, 11 – 14 July 2019
New Phase 3 data on the orally dissolving tablet (ODT) formulation of rimegepant have confirmed its rapid and sustained clinical benefits in acute migraine treatment, with efficacy seen as early as 60 minutes after treatment and continuing for up to 48 hours. The results from Study 303 (NCT03461757) support those from previous Phase 3 trials …
Read more »In the USA, nearly a third of people who experience at least four migraine days per month remain undiagnosed and a similar proportion seek emergency care for migraine, according to OVERCOME – an online survey of responses from more than 20,000 people living with migraine. Individuals were identified with migraine based on ICHD-3 criteria using …
Read more »Ubrogepant 50 mg has demonstrated efficacy in the treatment of acute migraine in patients for whom triptans are ineffective. Results of the Phase 3 ACHIEVE-I and ACHIEVE-II studies have shown that there is no difference in the magnitude of treatment effect between groups of patients classified as triptan-effective, triptan-ineffective and triptan-naïve. In the triptan-ineffective subgroup, …
Read more »In patients with episodic or chronic migraine and medication overuse, galcanezumab significantly improved mean monthly migraine headache days (MHDs) compared with placebo, and reduced average monthly medication overuse. These were the key findings of a post-hoc analysis of pooled data from the EVOLVE 1 and 2 studies, and from the REGAIN study. The number of …
Read more »Over half of people experiencing four or more migraine headache days (MHDs) per month in the USA may be current or previous opioid users. This conclusion is based on results from the OVERCOME (ObserVational survey of the Epidemiology, tReatment and Care Of MigrainE) web-based survey of 21,143 people with migraine which was carried out in …
Read more »Preclinical CGRP research has pointed to the posterior thalamic region (PoT) as a likely key integrator of light aversive signals that are modulated by CGRP in migraine.1 When CGRP was injected into the PoT of laboratory mice, the animals sought dark areas away from even dim light without showing increased anxiety behaviour. A similar effect …
Read more »
This program is funded in part via an independent educational grant from AbbVie.
Organon has provided sponsorship towards this independent resource. Organon has had no editorial input or control over content, nor opportunity to influence.
Financial support was provided as GMG Knowledge Gap Grant from Pfizer Inc, Pfizer have provided only financial support and had no input into the content provided.
